Molecular Profiles, a Nottingham-based CDMO, has secured a major pan-European formulation project, in which the company will be responsible for developing a topical and an oral formulation for Telormedix’s psoriasis products, TMX-302. The international research project, known as PAT (Psoriasis Anti-inflammatory Treatment), will also involve other consortium partners Biopta, Midatech Biogune and the University Hospital Zurich.
Telormedix, a clinical stage biopharmaceutical company, has raised funding from the European Eurostars Programme to coordinate the TMX-302 project, which will use Midatech’s glycan-coated gold nanoparticles formulated using Molecular Profiles’ expertise. Johanna Holldack, CEO at Telormedix, said in a press statement that “the team at Molecular Profiles will play a key role in developing new oral and topical formulations of TMX-302, both of which are viewed as practicable administration options for the treatment of psoriasis.”
Just a few weeks ago, Molecular Profiles announced the official opening of its new clinical manufacturing facility following a successful inspection from the Medical and Healthcare products Regulatory Agency (MHRA). Molecular Profiles was also recently acquired by Columbia Laboratories, a Boston-based drug development company.
“We are pleased to have been chosen as the formulation development partner for this high-profile, multi-partner project,” said Nikin Patel, CEO of Molecular Profiles in a press statement. “Our team is ready to apply our technologies to deliver a robust topical and oral formulation.” The company’s new facility can handle a range of dosage forms such as solids, liquids, semi-solids and inhaled products and has the capacity to manufacture controlled drugs and highly potent compounds up to OEB 4 level with batch scale of up to 30kg.
Source: Molecular Profiles